StockData

Exozymes Inc. (EXOZ) stock

EXOZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$3.43+0.12 (+3.63%)

Close on Nov 18, 2026Market cap $31.84MP/E –Yield –

Exozymes net income

Net income is the profit left for shareholders after every expense, interest and tax.

Exozymes's net income for the twelve months ending Sep 30, 2026 was -$10.14M. For fiscal 2025 it was -$9.16M.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$9.16M–
FY2024Dec 31, 2024-$5.86M–
FY2023Dec 31, 2023-$2.04M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$2.24M–
Q2 FY2026Jun 30, 2026-$2.88M–
Q1 FY2026Mar 31, 2026-$2.37M–
Q4 FY2025Dec 31, 2025-$2.66M–
Q3 FY2025Sep 30, 2025-$2.29M–
Q2 FY2025Jun 30, 2025-$2.36M–
Q1 FY2025Mar 31, 2025-$1.86M–
Q4 FY2024Dec 31, 2024-$1.84M–
Q3 FY2024Sep 30, 2024-$1.66M–
Q2 FY2024Jun 30, 2024-$1.36M–
Q1 FY2024Mar 31, 2024-$1.01M–
Q4 FY2023Dec 31, 2023-$1.10M–
Q3 FY2023Sep 30, 2023-$520.60K–
Q2 FY2023Jun 30, 2023-$178.08K–
Q1 FY2023Mar 31, 2023-$241.15K–

More Exozymes figures

See a number that looks wrong?